株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インドの医薬品市場の予測 (2018〜2028年):治療領域別・医薬品の種類別 (ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー) の予測と、代表的企業のプロファイル

Indian Pharmaceutical Market Forecast 2018-2028: Forecasts and Analysis by Therapeutic Area, Drug Type (Generic, OTC, Patented, Biosimilar), with Profiles of Leading Companies

発行 Visiongain Ltd 商品コード 346223
出版日 ページ情報 英文 188 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.94円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
インドの医薬品市場の予測 (2018〜2028年):治療領域別・医薬品の種類別 (ジェネリック医薬品、OTC医薬品、特許薬、バイオシミラー) の予測と、代表的企業のプロファイル Indian Pharmaceutical Market Forecast 2018-2028: Forecasts and Analysis by Therapeutic Area, Drug Type (Generic, OTC, Patented, Biosimilar), with Profiles of Leading Companies
出版日: 2018年02月22日 ページ情報: 英文 188 Pages
概要

インドの医薬品市場の総収益額は、2018年に287億米ドルに達する見通しです。今後も、人口高齢化や医療アクセスの改善、糖尿病などの慢性疾患の有病者数の増加などを受けて、拡大傾向が続くと見られています。

当レポートでは、インドの医薬品市場について調査分析し、市場の基本構造や背景事情、収益動向の予測、主要企業の評価、促進要因・抑制要因、見通しなど、体系的な情報を提供しています。

第1章 レポートの概要

第2章 インドの医療:概要

  • インド:人口統計指標の概要
  • インドの医療制度:概要
    • Rashtriya Swasthya Bima Yojana:最底辺の労働者向け医療保険の提供
  • インドの医療費の分析
  • インドの医薬品市場に対する当局の規制

第3章 インドの医薬品市場:考察と予測

  • 世界第3位の市場 (数量ベース)
  • 市場総収益額の予測 (今後11年間分)

第4章 インド国内の医療ニーズ

  • 各種疾患の有病率 (今後11年間分)
  • 各種疾患の発症率 (今後11年間分)
  • 各種疾患の死亡率 (今後11年間分)
    • インド国内の主な死因
    • 主な死因:死亡率の予測 (今後11年間分)

第5章 インドの医薬品市場:主な治療領域

  • 主な治療領域:概要
  • 主な治療領域の予測 (今後11年間分)
  • 感染症治療薬
    • 市場予測 (今後11年間分)
    • 市場促進・抑制要因
  • 心血管疾患治療薬
  • 胃腸疾患治療薬
  • 呼吸器疾患治療薬
  • 疼痛緩和薬/鎮痛剤
  • 糖尿病治療薬
  • ビタミン剤/ミネラル/栄養剤
  • 皮膚病治療薬
  • 中枢神経系 (CNS) 疾患治療薬
  • 婦人科疾患治療薬
  • その他の疾患の治療薬

第6章 インドの医薬品市場:主な薬剤の種類

  • インド市場における医薬品の種類:概要
  • 主な種類の医薬品の成長率予測 (今後11年間分)
  • ジェネリック医薬品 - インド市場の大半を占める存在
    • 市場予測 (今後11年間分)
    • 市場促進・抑制要因
  • OTC医薬品 (市販薬)
  • 特許医薬品
  • バイオシミラー医薬品

第7章 インドの医薬品市場の代表的企業

  • インドの医薬品市場:概要
    • インドの医薬品関連の特許法と、大手製薬企業の影響力
  • インド国内の大手製薬企業上位50社
  • Sun Pharmaceuticals Industries Limited
    • 業績動向 (過去10年間分)
    • 近年の資本取引動向
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited. India
  • Lupin

第8章 インドの医薬品市場の定性分析

  • インドの医薬品市場:促進・抑制要因
  • インドの医薬品市場のSWOT分析
  • 強み
    • 医療制度への投資拡大
    • 疾病負荷・GDPの双方の増大
    • インドの総人口:2030年には世界最大となる
    • 製薬産業の外注先として有望なインド
  • 弱み
    • 厳格な価格規制による市場への悪影響
    • 貧弱な医療インフラによる、潜在的市場の縮小
    • 激しい市場競争に伴う薬価の下落
  • 機会
    • 世界規模でのジェネリック医薬品の需要増加
    • 国家農村健康ミッション (NRHM):農村部の医療アクセスの改善
    • 多国籍企業 (MNC) による巨額の投資の見通し
    • 革新的なバイオテクノロジー部門:特許満了を好機として躍進
  • 脅威
    • ジェネリック医薬品:他の低コスト輸出国の台頭
    • インド政府は今後も医療費の増額傾向を維持するのか?
    • 当局からの近年の警告と輸出禁止令:製薬企業の自信喪失
  • ポーターのファイブフォース分析
    • 企業間競争 (高)
    • 新規参入企業の脅威 (低)
    • サプライヤーの交渉力 (中)
    • バイヤーの交渉力 (高)
    • 代替製品の脅威 (低)

第9章 結論

  • インドの医薬品市場:世界市場でのシェアの拡大
  • 慢性疾患の有病者数の急増
  • 市場促進要因
  • 市場抑制要因
  • 分析結果

第10章 付録

目次
Product Code: PHA0286

What can be expected from the Indian Pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2028, assessing data, trends, opportunities and prospects there.

Our 188-page report provides 104 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of the Indian pharmaceutical market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2018-2028 and other analyses show you commercial prospects

Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2028? Our study forecasts revenues in the following Indian Pharmaceutical submarkets:

  • Generic Drugs
  • Over-The-Counter (OTC) Drugs
  • Patented Drugs
  • Biosimilars

See revenue forecasts for the leading therapeutic areas

How will leading therapeutic areas perform to 2028? Our study forecasts revenues in therapeutic areas including:

  • Infectious disease drugs
  • Cardiovascular disease drugs
  • Gastro-intestinal drugs
  • Respiratory disease
  • Pain relief / analgesics
  • Diabetes
  • Vitamins / Minerals / Nutrients
  • Dermatology
  • Central Nervous System (CNS)
  • Gynaecology

image1

Leading companies and potential for market growth

Overall revenue for the Indian Pharmaceutical market will reach over $28.7bn in 2018, our work forecasts. We predict strong revenue growth through to 2028. An ageing population, increasing access to healthcare and increasing incidence of chronic diseases, especially diabetes and cardiovascular disease, will drive sales to 2028.

Our work analyses the key companies in the market. See visiongain's analysis of leading companies, including these:

  • Sun Pharmaceutical Industries Limited
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited (GSK India)
  • Pfizer Limited. India
  • Lupin Pharmaceuticals, Inc.,

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Indian pharmaceutical industry?

Our new report discusses issues and events affecting the Indian pharmaceutical market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Changing regulatory landscape challenging new entrants and major market players alike
  • Emerging drug types with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Indian Pharmaceutical Market Forecast 2018-2028 report helps you

In summary, our 188-page report gives you the following knowledge:

  • Revenue forecasts to 2028 for the Indian Pharmaceutical market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2028 for each major submarket - discover prospects for leading pharmaceutical products in the following areas: Infectious disease drugs, Cardiovascular disease drugs, Gastro-intestinal drugs, Respiratory disease, Pain relief / analgesics, Diabetes, Vitamins / Minerals / Nutrients, Dermatology, Central Nervous System (CNS), Gynaecology
  • Revenue forecasts to 2028 for the leading drug types - generics, OTC products, patented drugs and biosimilars
  • Assessment of leading companies - analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Molecular Diagnostics market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 The Indian Pharmaceutical Market Overview
  • 1.2 Indian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Indian Healthcare: Overview

  • 2.1 India: Demographic Indicators Overview
  • 2.2 Indian Healthcare System: Overview
    • 2.2.1 Rashtriya Swasthya Bima Yojana - Bringing Healthcare Coverage to India's Poorest Workers
  • 2.3 Analysis of India's Healthcare Expenditure
  • 2.4 State Bodies Regulating the Indian Pharmaceutical Market
    • 2.4.1 The Drugs and Cosmetics Act, 1940

3. Indian Pharmaceutical Market: Discussions and Predictions 2018-2028

  • 3.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume, 2015
  • 3.2 Indian Pharmaceutical Market: Overall Revenue Forecast 2018-2028

4. Medical Treatment Needs in India, 2018-2028

  • 4.1 Disease Prevalence in India, 2018-2028
  • 4.2 Disease Incidence in India, 2018-2028
  • 4.3 Disease Mortality Rates in India, 2018-2028
    • 4.3.1 Top Causes of Death in India
    • 4.3.2 Top Causes of Death in India: Mortality Projections, 2018-2028

5. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2018-2028

  • 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2015
  • 5.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2018-2028
  • 5.3 Infectious Disease Drugs: Overview, 2015
    • 5.3.1 Infectious Disease Drugs Market: Forecast, 2018-2028
    • 5.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2015
    • 5.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death
    • 5.3.4 Tuberculosis Still Rife in India
    • 5.3.5 Malaria, Risk and Opportunity
    • 5.3.6 HIV in India: Growing Therapeutic Area Worth Watching
    • 5.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment, 2018-2028
  • 5.4 Cardiovascular Therapeutic Segment: Overview, 2017
    • 5.4.1 Cardiovascular Disease - India's Leading Cause of Death, 2017
    • 5.4.2 Cardiovascular Drugs Market: Forecast, 2018-2028
    • 5.4.3 Drivers and Restraints for the Indian Cardiovascular Drugs Market, 2018-2028
  • 5.5 Gastro-Intestinal Therapeutic Segment: Overview, 2015
    • 5.5.1 Gastro-Intestinal Drugs Market: Forecast, 2018-2028
    • 5.5.2 Gastro-Intestinal Drugs in India: Challenges and Opportunities
    • 5.5.3 Drivers and Restraints for the Gastro-Intestinal Drugs Segment, 2017
  • 5.6 Respiratory Therapeutic Segment: Overview, 2017
    • 5.6.1 Respiratory Disease Drugs Market: Forecast, 2018-2028
    • 5.6.2 Drivers and Restraints for the Respiratory Diseases Segment, 2017
  • 5.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2017
    • 5.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2018-2028
    • 5.7.2 Drivers and Restraints for the Pain Relief / Analgesics Drugs Segment, 2017
  • 5.8 Diabetes Therapeutic Segment: Overview, 2017
    • 5.8.1 Diabetes Drugs Market: Forecast, 2018-2028
    • 5.8.2 Drivers and Restraints for the Diabetes Drugs Segment, 2017
  • 5.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2017
    • 5.9.1 Vitamins / Minerals / Nutrients Drugs Market: Forecast, 2018-2028
    • 5.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
    • 5.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Drugs Segment, 2017
  • 5.10 Dermatological Therapeutic Segment: Overview, 2017
    • 5.10.1 Dermatological Drugs Market: Forecast, 2018-2028
    • 5.10.2 Drivers and Restraints for the Dermatological Drugs Segment, 2017
  • 5.11 Central Nervous System (CNS) Therapeutics: Overview, 2015
    • 5.11.1 CNS Drugs Market: Forecast, 2018-2028
    • 5.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2017
    • 5.11.3 India's Aging Population: Driver for the CNS Segment
    • 5.11.4 Drivers and Restraints for the CNS Drugs Segment, 2017
  • 5.12 Gynaecological Treatment Market Overview: 2017
    • 5.12.1 Infant Mortality Still High in India
    • 5.12.2 Indian Gynaecological Treatments Market: Forecast, 2018-2028
    • 5.12.3 Drivers and Restraints for the Gynaecological Segment, 2017
  • 5.13 Other Pharmaceutical Products Market Overview: 2017
    • 5.13.1 Incidence of Cancer in India is Rising
    • 5.13.2 Indian Other Treatments Market: Forecast, 2018-2028

6. Indian Pharmaceutical Market: Leading Drug Types, 2018-2028

  • 6.1 Drug Types in the Indian Market: Overview, 2017
  • 6.2 Growth Forecasts for Leading Drug Types in India, 2018-2028
  • 6.3 Generic Drugs Dominate the Indian Pharmaceutical Market
    • 6.3.1 Indian Generics: Overview, 2017
    • 6.3.2 Indian Generic Drugs Market: Forecast, 2018-2028
    • 6.3.3 Branded Generics Preferred by Many Indian Patients
    • 6.3.4 Drivers and Restraints for the Generic Drug Market in India, 2017
  • 6.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2017
    • 6.4.1 Indian OTC Market: Forecast, 2018-2028
    • 6.4.2 Drivers and Restraints of the Indian OTC Market
  • 6.5 Indian Patented Drugs Market: Overview, 2017
    • 6.5.1 Indian Patented Drugs Market: Forecasts, 2018-2028
    • 6.5.2 Drivers and Restraints for the Indian Patented Drugs Market
  • 6.6 Indian Biosimilar Drugs, 2017
    • 6.6.1 Indian Biosimilar Drugs Market: Forecast, 2018-2028
    • 6.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
    • 6.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market

7. The Leading Companies in the Indian Pharmaceutical Market, 2018-2028

  • 7.1 Indian Pharmaceutical Market Overview
    • 7.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
  • 7.2 Top 50 Domestic Indian Pharmaceutical Companies, 2017
  • 7.3 Sun Pharmaceuticals Industries Limited
    • 7.3.1 Sun Pharma: Global Presence
    • 7.3.1.1 Sun Pharmaceutical Sales by Region, 2017
    • 7.3.2 Sun Pharmaceuticals Business Performance 2008-2017
    • 7.3.3 Sun Pharmaceutical: The Acquisition of Ranbaxy Laboratories is the Largest Ever Deal Made by an Indian Pharmaceutical Company
    • 7.3.3.1 Other Major M&A Activity
  • 7.4 Abbott Healthcare Private Limited (Abbott India)
    • 7.4.1 Abbott India: Business Performance 2007-2017
    • 7.4.3 Abbott India: Major and Recent M&A Activity
  • 7.5 Cipla Ltd.
    • 7.5.1 Cipla: Business Performance 2006-2015
  • 7.6 Cadila Healthcare Limited
    • 7.6.1 Cadila: Business Performance 2008-2017
    • 7.6.2 Cadila Healthcare Revenue by Therapeutic Area 2017
  • 7.7 GlaxoSmithKline Pharmaceuticals Limited
    • 7.7.1 GlaxoSmithKline India: Business Performance 2008-2017
  • 7.8 Pfizer Limited. India
    • 7.8.1 Pfizer India: Business Performance 2008-2017
  • 7.9 Lupin
    • 7.9.1 Lupin: Business Performance 2008-2017
    • 7.9.2 Lupin Revenue by Therapeutic Area, 2017

8. Qualitative Analysis of the Indian Pharmaceutical Market, 2015

  • 8.1 Indian Pharmaceutical Market: Drivers and Restraints
  • 8.2 SWOT Analysis of the Indian Pharmaceutical Market, 2018-2028
  • 8.3 Strengths
    • 8.3.1 Increasing Investment in the Healthcare System
    • 8.3.2 The Disease Burden and GDP Both Growing
    • 8.3.3 India's Population Set to Become the World's Largest by 2030
    • 8.3.4 India Popular for Pharmaceutical Outsourcing
  • 8.4 Weaknesses
    • 8.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceutical Market
    • 8.4.2 Poor Infrastructure Threatens to Hinder Market Potential
    • 8.4.3 Intense Competition Driving Down Drug Prices
  • 8.5 Opportunities
    • 8.5.1 Global Demand for Generics Rising
    • 8.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
    • 8.5.3 Significant Investment from MNCs Expected
    • 8.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
  • 8.6 Threats
    • 8.6.1 Rise of Other Low-Cost Generic Exporters
    • 8.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
    • 8.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
  • 8.7 Porter's Five Forces Analysis of the Indian Pharmaceutical Market
    • 8.7.1 Rivalry Among Competitors [High]
    • 8.7.2 Threat of New Entrants [Low]
    • 8.7.3 Power of Suppliers [Medium]
    • 8.7.4 Power of Buyers [High]
    • 8.7.5 Threat of Substitutes [Low]

9. Conclusion

  • 9.1 The Indian Pharmaceutical Market: Growing Global Market Share
  • 9.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
  • 9.3 Commercial Drivers of the Indian Pharmaceutical Market
  • 9.4 Commercial Restraints of the Indian Pharmaceutical Market
  • 9.5 Concluding Remarks

10. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
  • Figure 2.1 Indian Population: Rural and Urban Populations (Mn),1960-2020
  • Figure 2.2 Indian Population: Total Population (Mn) and Annual Population Growth Rate (%), 1960-2020
  • Figure 2.3 Indian GDP ($bn) and GDP growth (%), 2010-2020
  • Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2006-2015
  • Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2013
  • Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
  • Figure 3.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 4.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Figure 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2017
  • Figure 5.2 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2023
  • Figure 5.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2028
  • Figure 5.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
  • Figure 5.6 Infectious Disease Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.8 Cardiovascular Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.9 The Indian Gastro-Intestinal Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.10 Gastro-intestinal Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.11 The Indian Respiratory Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.12 Respiratory Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.13 The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.14 Pain Relief / Analgesics Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.15 The Indian Diabetes Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.16 Diabetes Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.17 The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.18 Vitamins / Minerals / Nutrients Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.19 The Indian Dermatological Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.20 Dermatological Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.21 The Indian CNS Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.22 CNS Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.23 The Indian Gynaecological Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 5.24 Gynaecological Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 5.25 The Indian Other Drugs Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 6.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2017
  • Figure 6.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2023
  • Figure 6.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2028
  • Figure 6.4 The Indian Generic Drug Market: Revenue ($bn) andAGR(%), 2018-2028
  • Figure 6.5 Generic Drug Market in India: Drivers and Restraints, 2018-2028
  • Figure 6.6 The Indian OTC Drug Market: Revenue ($bn) and AGR (%), 2018-2028
  • Figure 6.7 OTC Drug Market in India: Drivers and Restraints, 2018-2028
  • Figure 6.8 The Indian Patented Drugs Market: Revenue ($bn)andAGR(%), 2018-2028
  • Figure 6.9 Patented Drugs Market in India: Drivers and Restraints, 2018-2028
  • Figure 6.10 The Indian Biosimilar Drugs Market: Revenue ($bn) andAGR (%), 2018-2028
  • Figure 6.11 Biosimilar Drug Market in India: Drivers and Restraints, 2018-2028
  • Figure 7.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY2017
  • Figure 7.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
  • Figure 7.3 Abbott India: Revenue (Rsm) and AGR (%), 2006-2017
  • Figure 7.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 7.5 Cadila Healthcare Ltd.: Revenue (Rs. m) and AGR (%), 2008-2017
  • Figure 7.6 Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2017
  • Figure 7.7 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
  • Figure 7.8 Pfizer India: Revenue (Rs.m) and AGR (%), 2006-2015
  • Figure 7.9 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 7.10 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Figure 8.1 Indian Pharmaceutical Market: Drivers and Restraints, 2018-2028
  • Figure 8.2 Porter's Five Forces Analysis of the Indian Pharmaceutical Market, 2018-2028

List of Tables

  • Table 1.1 Rupee to Dollar Historical Exchange Rates 2006-2015
  • Table 3.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%),2018-2028
  • Table 4.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Table 4.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
  • Table 4.3 Causes of Death in India by World Ranking, 2014
  • Table 5.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2017, 2023, 2028
  • Table 5.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2028
  • Table 5.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2028
  • Table 5.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.5 The Indian Gastro-Intestinal Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.6 The Indian Respiratory Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.7 The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.8 The Indian Diabetes Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.9 The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.10 The Indian Dermatological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.11 The Indian CNS Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.12 The Indian Gynaecological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 5.13 The Indian Other Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 6.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 and 2026
  • Table 6.10 Selected Late-Stage Biosimilar Pipeline Products, 2015
  • Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2018-2028
  • Table 6.3 The Indian Generic Drug Market: Revenue ($bn), AGR (%) and CAGR (%) 2018-2028
  • Table 6.4 The Indian OTC Drug Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 6.5 The Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 6.6 Selected Biosimilar Therapeutics on the Indian Market, 2017
  • Table 6.7 Selected Biosimilar Therapeutics on the Indian Market, 2017 (continued)
  • Table 6.8 The Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2028
  • Table 6.9 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
  • Table 7.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs.m), Revenue ($m) and Market Share (%), 2017
  • Table 7.2 Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, FY2017
  • Table 7.3 Sun Pharmaceuticals: Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 7.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
  • Table 7.5 Abbott India: Market Share (%) and Market Rank of Key Brands
  • Table 7.6 Abbott India: Revenue (Rs.m), AGR (%) and CAGR (%), 2006-2017
  • Table 7.7 Cipla: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 7.8 Cipla: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
  • Table 7.9 Cadila Healthcare Ltd.: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2016
  • Table 7.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
  • Table 7.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017 (continued)
  • Table 7.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
  • Table 7.12 GlaxoSmithKline India Total Revenue (Rs.m), AGR (%) and CAGR (%), 2007-2017
  • Table 7.13 Pfizer India: Leading Brands on the Indian Market 2017
  • Table 7.14 Pfizer India: Total Revenue (Rs.m),AGR (%) and CAGR (%), 2008-2017
  • Table 7.15 Lupin: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.1 SWOT Analysis of the Indian Pharmaceutical Market, 2018-2028

Companies Listed

  • Abbott Laboratories
  • Abbott India
  • Able Labs
  • Ajanta Pharma Ltd
  • Akumentis Healthcare Ltd
  • Albert David Ltd
  • Alembic
  • Alkem
  • Apex Laboratories Pvt. Ltd
  • Aristo Pharma
  • AstraZeneca
  • Bayer
  • Bharat Serums
  • Biocon Ltd
  • Bioviz Technologies
  • Blue Cross Laboratories Ltd.
  • Cadila Healthcare Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Caraco Pharmaceutical Laboratories
  • Cattern Chemical Inc.
  • Cipla
  • Claris Lifesciences
  • Daiichi Sankyo
  • Divis Laboratories
  • Dr Reddy's Labs
  • DUSA Pharmaceuticals Inc.
  • Emcure
  • Epirus Biopharmaceuticals
  • Eris Lifesciences
  • FDC
  • Fourrts (India) Laboratories Pvt, Ltd
  • Franco India
  • Gennova Biopharmaceuticals
  • Gland Pharma
  • Glenmark Pharma
  • GlaxoSmithKline
  • GSK India
  • Hetero Drugs Ltd
  • Indoco
  • Intas Pharma
  • Intrexon
  • Ipca Labs
  • Janssen
  • JB Chemicals
  • Lonza
  • Lupin
  • Macleods
  • Mankind
  • Medley Pharmaceuticals Ltd
  • Medpro Pharmaceutica (Pty) Ltd.
  • Megafine Pharma
  • Merck & Co., Inc.
  • Merck KGaA
  • Merieux Alliance
  • Meyer Organics
  • Micro Labs
  • MSD Pharma
  • Natco
  • Novartis
  • Novartis India
  • Pfizer India
  • Pharmalucence
  • Piramal Healthcare
  • Raptakos, Brett & Co. Ltd
  • Sandoz (Novartis)
  • Sanofi
  • Sanofi India
  • Serum Institute of India
  • Shantha Biotechnics
  • Sun Pharmaceuticals Industries Ltd
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Ltd.
  • The Himalaya Drug Company
  • Torrent Pharma
  • Unichem
  • URL
  • USV
  • Virchow Biotech
  • Wallace + Indi Pharma
  • Win-Medicare
  • Wockhardt
  • Zenotech Laboratories

List of Organizations

  • Central Drugs Standard Control Organisation (CDSCO)
  • Competition Commission of India (CCI)
  • Drug Technical Advisory Board (DTAB)
  • Drug Consultative Committee (DCC)
  • European Medicines Agency
  • High Court of Punjab and Haryana
  • Indian Patent Office
  • (Japan's) Minstry of Health, Labour and Welfare (MHLW)
  • Medical Council of India
  • (Indian) Ministry of Health
  • National AIDS Control Organisation (NACO)
  • (Australia's) Therapeutic Goods Administration (TGA)
  • UK Medicines & Healthcare Products Regulatory Agency (MHRA)
  • US Federal Trade Commission (FTC)
  • US Food and Drug Administration (FDA)
  • UNAIDS
  • World Bank
  • World Health Organisation (WHO)
  • World Trade Organisation (WTO)
Back to Top